BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pascua PNQ, Mostafa HH, Marathe BM, Vogel P, Russell CJ, Webby RJ, Govorkova EA. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection. Sci Rep 2017;7:7345. [PMID: 28779075 DOI: 10.1038/s41598-017-07433-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Mifsud EJ, Tai CM, Hurt AC. Animal models used to assess influenza antivirals. Expert Opin Drug Discov 2018;13:1131-9. [PMID: 30362841 DOI: 10.1080/17460441.2018.1540586] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
2 Chen L, Han X, Li Y, Zhang C, Xing X. Impact of early neuraminidase inhibitor treatment on clinical outcomes in patients with influenza B-related pneumonia: a multicenter cohort study. Eur J Clin Microbiol Infect Dis 2020;39:1231-8. [PMID: 32026193 DOI: 10.1007/s10096-020-03835-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
3 Marathe BM, Mostafa HH, Vogel P, Pascua PNQ, Jones JC, Russell CJ, Webby RJ, Govorkova EA. A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment. Antiviral Res 2017;148:20-31. [PMID: 29100887 DOI: 10.1016/j.antiviral.2017.10.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
4 Pascua PNQ, Marathe BM, Bisen S, Webby RJ, Govorkova EA. Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutions. Antiviral Res 2020;173:104669. [PMID: 31790712 DOI: 10.1016/j.antiviral.2019.104669] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Fage C, Abed Y, Checkmahomed L, Venable MC, Boivin G. In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors. Viruses 2018;11:E6. [PMID: 30583488 DOI: 10.3390/v11010006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pascua PNQ, Marathe BM, Vogel P, Webby RJ, Govorkova EA. Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model. J Antimicrob Chemother 2019;74:1333-41. [PMID: 30715325 DOI: 10.1093/jac/dky560] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019;167:45-67. [PMID: 30974127 DOI: 10.1016/j.antiviral.2019.04.006] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 26.3] [Reference Citation Analysis]
8 Scott LJ. Peramivir: A Review in Uncomplicated Influenza. Drugs 2018;78:1363-70. [PMID: 30196350 DOI: 10.1007/s40265-018-0981-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
9 Wang X, Tian Y. Microbiological and chest X-ray studies on influenza B virus-associated pneumonia. Indian J Med Microbiol 2018;36:401-7. [PMID: 30429395 DOI: 10.4103/ijmm.IJMM_18_66] [Reference Citation Analysis]
10 Marathe BM, Asthagiri Arunkumar G, Vogel P, Pascua PNQ, Jones J, Webby RJ, Krammer F, Govorkova EA. Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus. Antimicrob Agents Chemother 2020;64:e00284-20. [PMID: 32631823 DOI: 10.1128/AAC.00284-20] [Reference Citation Analysis]